ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S.

ERYTECH announced today that it has received clearance of its Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its product ERYASP®, L-asparaginase loaded erythrocytes, in patients 40 years or older with newly diagnosed Acute Lymphoblastic Leukemia (ALL).